Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.

Ross McD Young, Bruce R Lawford, Mark Barnes, Simon C Burton, Terry Ritchie, Warren K Ward, Ernest P Noble

Alcohol Research Center, Neuropsychiatric Institute, University of California, Los Angeles, CA 90024-1759, USA. epnoble@ucla.edu

The British journal of psychiatry : the journal of mental science 2004 Aug

filter terms:

Hyperprolactinaemia induced by D(2) dopamine receptor antagonist antipsychotic medication can result in significant health problems. To examine the role of DRD2 polymorphism on prolactin levels in patients treated with antipsychotic medication. Antipsychotic drugs with different degrees of D(2) receptor binding were given to 144 patients with schizophrenia. Serum prolactin levels were obtained and Taq1A DRD2 alleles were determined. Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). In the combined medication group, patients with the DRD2(*)A1allele had 40% higher prolactin levels than patients without this allele. In patients treated with clozapine (the loosest D(2) receptor binding agent), patients with the DRD2(*)A1allele had prolactin levels twice those of patients without this allele. Patients with the DRD2A1 allele receiving antipsychotic medications had higher prolactin levels and were overrepresented among those with hyperprolactinaemia, suggesting greater functional D(2) receptor binding in this group.

Citation

Ross McD Young, Bruce R Lawford, Mark Barnes, Simon C Burton, Terry Ritchie, Warren K Ward, Ernest P Noble. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British journal of psychiatry : the journal of mental science. 2004 Aug;185:147-51